A comparison of various aggregation functions in multi-criteria decision analysis for drug benefit–risk assessment
Open Access
- 19 January 2022
- journal article
- research article
- Published by SAGE Publications in Statistical Methods in Medical Research
- Vol. 31 (5) , 899-916
Abstract
Multi-criteria decision analysis is a quantitative approach to the drug benefit–risk assessment which allows for consistent comparisons by summarising all benefits and risks in a single score. The multi-criteria decision analysis consists of several components, one of which is the utility (or loss) score function that defines how benefits and risks are aggregated into a single quantity. While a linear utility score is one of the most widely used approach in benefit–risk assessment, it is recognised that it can result in counter-intuitive decisions, for example, recommending a treatment with extremely low benefits or high risks. To overcome this problem, alternative approaches to the scores construction, namely, product, multi-linear and Scale Loss Score models, were suggested. However, to date, the majority of arguments concerning the differences implied by these models are heuristic. In this work, we consider four models to calculate the aggregated utility/loss scores and compared their performance in an extensive simulation study over many different scenarios, and in a case study. It is found that the product and Scale Loss Score models provide more intuitive treatment recommendation decisions in the majority of scenarios compared to the linear and multi-linear models, and are more robust to the correlation in the criteria.Keywords
All Related Versions
Funding Information
- Medical Research Council (MC UU 00002/14)
- National Institute for Health Research (NIHR300576)
This publication has 19 references indexed in Scilit:
- Multiple Criteria Decision Analysis for Health Care Decision Making—Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task ForceValue in Health, 2016
- Multiple Criteria Decision Analysis for Health Care Decision Making—An Introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task ForceValue in Health, 2016
- Quantitative benefit–risk assessment by MCDA of the quadrivalent HPV vaccine for preventing anal cancer in malesExpert Review of Vaccines, 2015
- A Bayesian approach to probabilistic sensitivity analysis in structured benefit‐risk assessmentBiometrical Journal, 2015
- A case study using the PrOACT‐URL and BRAT frameworks for structured benefit risk assessmentBiometrical Journal, 2015
- Assessing the Value of Healthcare Interventions Using Multi-Criteria Decision Analysis: A Review of the LiteraturePharmacoEconomics, 2014
- A stochastic multicriteria model for evidence‐based decision making in drug benefit‐risk analysisStatistics in Medicine, 2011
- Measures for Conducting Comparative Benefit: Risk AssessmentDrug Information Journal, 2008
- Current Assessment of Risk–Benefit by Regulators: Is It Time to Introduce Decision Analyses?Clinical Pharmacology & Therapeutics, 2007
- A quantitative approach to benefit-risk assessment of medicines – part 1: the development of a new model using multi-criteria decision analysisPharmacoepidemiology and Drug Safety, 2007